Researchers Studying Oral Drug to Treat Pediatric Adamantinomatous Craniopharyngioma (ACP)
Phase: Recruiting
First Posted: January
Condition(s): Adamantinomatous Craniopharyngioma (ACP)
NCT Number: NCT05286788 Other Study ID Number(s): CONNECT2108
What Is the Purpose of This Study?
To learn more about the effects of the oral tablet drug binimetinib in patients with adamantinomatous craniopharyngioma (ACP) who may or may not have undergone surgery or radiation as it may help shrink this type of brain tumor or slow its growth.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have progressive or recurrent measurable ACP following radiation therapy.
- Have measurable ACP and have undergone surgery but have NOT undergone prior irradiation.
- Are 1-25 years old.
For a full list of eligibility requirements, visit https://www.clinicaltrials.gov/study/NCT05286788
What Will Happen During This Study?
Patients will take oral medication twice a day for up to 26 cycles. Each cycle is 4 weeks long.
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
Craniopharyngioma
Craniopharyngioma is a rare tumor that develops at the central, bottom portion of the brain. It can affect the pituitary gland, optic pathway, and hypothalamus.
Brain Tumors
Brain tumors are the most common solid tumors in children. Primary brain tumors start in the brain and usually do not spread outside the brain tissue.